Well one just has to look at HGSI or DNDN over a 12 month period...

Well one just has to look at HGSI or DNDN over a 12 month period to see what good clinical results can do to a share price. The OVATURE data is very close to being released and since it's double blinded, it's difficult to read anything into share price weakness other than people are bored and have lost faith. The results are just as capable of impressing the market as Phenoxodiol was when NRT was $8... it's now 40c so the upside surprise could be huge... but we need positive results. I'm long NRT.